[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587367":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":110,"collaborators":11,"id":112,"slug":11,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":11,"eligibilityCriteria":116,"healthyVolunteers":113,"sex":117,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":11,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":11,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"B019","EXPERIMENTAL",null,[13],"Biological: B019",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","B019： Intravenous infusion, 1.0×10\\^6 CAR T cell\u002Fkg-10.0×10\\^6 CAR T cell\u002Fkg",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Jing Chen","CONTACT","0086-021-38626161","chenjing@scmc.com.cn",[26,40,51,59,70,77,88,99],{"facility":27,"status":28,"city":29,"state":11,"zip":11,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Peking University People's Hospital","RECRUITING","Beijing","China",{"type":32,"coordinates":33},"Point",[34,35],116.39723,39.9075,{"lat":35,"lon":34},[38],{"name":39,"role":22,"phone":11,"phoneExt":11,"email":11},"Yifei Cheng",{"facility":41,"status":28,"city":42,"state":11,"zip":11,"country":30,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"Jiangxi Province pediatric hospital","Nanchang",{"type":32,"coordinates":44},[45,46],115.85306,28.68396,{"lat":46,"lon":45},[49],{"name":50,"role":22,"phone":11,"phoneExt":11,"email":11},"Fei He",{"facility":52,"status":28,"city":42,"state":11,"zip":11,"country":30,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"The First Affiliated Hospital of Nanchang University",{"type":32,"coordinates":54},[45,46],{"lat":46,"lon":45},[57],{"name":58,"role":22,"phone":11,"phoneExt":11,"email":11},"Fei Li",{"facility":60,"status":28,"city":61,"state":11,"zip":11,"country":30,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Children's Hospital of Shanghai","Shanghai",{"type":32,"coordinates":63},[64,65],121.45806,31.22222,{"lat":65,"lon":64},[68],{"name":69,"role":22,"phone":11,"phoneExt":11,"email":11},"Jingbo Shao",{"facility":71,"status":28,"city":61,"state":11,"zip":11,"country":30,"cosmosGeoPoint":72,"geoPoint":74,"contacts":75},"Shanghai Children's Medical Center",{"type":32,"coordinates":73},[64,65],{"lat":65,"lon":64},[76],{"name":21,"role":22,"phone":11,"phoneExt":11,"email":11},{"facility":78,"status":28,"city":79,"state":11,"zip":11,"country":30,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Children's Hospital of Soochow University","Suzhou",{"type":32,"coordinates":81},[82,83],120.59538,31.30408,{"lat":83,"lon":82},[86],{"name":87,"role":22,"phone":11,"phoneExt":11,"email":11},"Shaoyan Hu",{"facility":89,"status":28,"city":90,"state":11,"zip":11,"country":30,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Tongji Hospital","Wuhan",{"type":32,"coordinates":92},[93,94],114.26667,30.58333,{"lat":94,"lon":93},[97],{"name":98,"role":22,"phone":11,"phoneExt":11,"email":11},"Jia Kui",{"facility":100,"status":28,"city":101,"state":11,"zip":11,"country":30,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"The Affiliated Hospital of Xuzhou Medical University","Xuzhou",{"type":32,"coordinates":103},[104,105],117.28386,34.20442,{"lat":105,"lon":104},[108],{"name":109,"role":22,"phone":11,"phoneExt":11,"email":11},"Zhenyu Li",{"type":111,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100587367",false,"NCT06927466","A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.","Inclusion Criteria:\n\n1. The patient himself\u002Fherself , and\u002For his\u002Fher legal guardian, agree to participate in the trial and sign the informed consent form；\n2. Meet the diagnostic criteria for recurrent or refractory acute B cell lymphoblastic leukemia；\n3. Documentation of CD19\u002FCD22 tumor expression\n\n3\\. Liver, kidney, lung and heart function meet requirements; 4. Expected survival \\>3 months; 5. Women of childbearing age and all post-adolescent male participants are willing to use highly effective contraceptive methods within 1 year after the infusion of B019 injection. At the same time, the subject should promise not to donate eggs or sperm for assisted reproduction for 1 year after the cell infusion.\n\n\\-\n\nExclusion Criteria:\n\n1. Active CNS involvement by malignancy；\n2. Isolated extramedullary leukemia recurrence；\n3. Subjects with ≥grade 2 acute or moderate to severe chronic graft-versus-host disease (GVHD) within 4 weeks prior to screening;\n4. Has had treatment with any prior CAR-T therapy or other therapy abandoned in protocal.\n\n4\\. Subjects who received therapy abandoned in protocal before PBMC (peripheral blood mononuclear cells) collection or before B019 injection; 5.Active other malignancy in 5 years. 6. Subjects who are positive for any of HBsAg, HBeAg, HBeAb, HBcAb, HCV-RNA, HIV EBV DNA, CMV DNA, HTLV-ab.\n\n7\\. Other situations deemed inappropriate for participation in this study by the investigator.\n\n\\-","ALL","3 Years","25 Years",{"count":121,"type":122},33,"ESTIMATED","INTERVENTIONAL",[125],"PHASE1","The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.",[128],"Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia","2025-05-21",{"date":131,"type":132},"2025-05-22","ACTUAL",{"date":134,"type":132},"2024-09-19",{"date":136,"type":122},"2028-06-30",{"name":5,"class":6},8]